On April 27, 2026 Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, reported that two abstracts highlighting preclinical data from its proprietary RSwitch technology, which enables the fine-tuning of transgene levels in gene and cell therapy applications, have been accepted for oral presentation at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Title: Small Molecule–regulated RNA switch achieves therapeutically safe levels of Frataxin in mouse models of Friedreich’s Ataxia.
Abstract #: 69
Session Title: Neurologic diseases I
Date and Time: May 12, 2026; 10:45 – 11:00 a.m. ET
Presenter: Jon Dempersmier, Ph.D., Senior Scientist, Rgenta Therapeutics

Title: Deep-learning guided optimization of a small molecule-regulated RNA switch for titratable AAV transgene expression.
Abstract #: 1908
Session Title: Engineering programmable gene therapy systems
Date and Time: May 13, 2026; 11:15 a.m. ET
Presenter:
Ian McLachlan, Ph.D., Senior Scientist, Rgenta Therapeutics

About RSwitch
RSwitch is a proprietary regulatable gene therapy system that enables oral, small molecule drug control of transgene levels in gene and cell therapy applications. RSwitch encodes a "dimmer" switch that makes the expression of transgene dependent on the administration of an oral small molecule drug that controls the system. Only when the drug is administered is the system activated. Furthermore, the level of gene expression is dependent on how much drug is administered. This precise gene control has the potential to enable fine control of the expression of a therapeutic protein. Rgenta has demonstrated the RSwitch system’s feasibility in vitro and in vivo, achieving dose-dependent expression of transgenes following small molecule administration. RSwitch technology offers versatile control across multiple gene and cell therapy applications, and the company is actively exploring strategic partnerships.

(Press release, Rgenta Therapeutics, APR 27, 2026, View Source [SID1234664824])